Agentix Corp. (AGTX)
USD 0.05
(-35.88%)
USD 0.05
(-35.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.37 Million USD | 0.0% |
| 2021 | -1.34 Million USD | 0.0% |
| 2019 | -121.31 Thousand USD | 9.72% |
| 2018 | -134.37 Thousand USD | 59.77% |
| 2017 | -333.99 Thousand USD | -14.21% |
| 2016 | -292.43 Thousand USD | -66.98% |
| 2015 | -175.12 Thousand USD | 16.16% |
| 2014 | -208.87 Thousand USD | -317.76% |
| 2013 | -50 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -401.13 Thousand USD | -13.43% |
| 2023 Q4 | -353.63 Thousand USD | 0.0% |
| 2023 Q3 | -353.63 Thousand USD | 16.66% |
| 2023 FY | -1.37 Million USD | 0.0% |
| 2023 Q1 | -164.65 Thousand USD | 91.84% |
| 2023 Q2 | -424.33 Thousand USD | -157.71% |
| 2022 Q3 | -186.97 Thousand USD | 23.4% |
| 2022 Q1 | -173.24 Thousand USD | 75.5% |
| 2022 Q2 | -244.1 Thousand USD | -40.9% |
| 2022 Q4 | -2.01 Million USD | -978.93% |
| 2021 Q4 | -706.96 Thousand USD | -226.21% |
| 2021 FY | -1.34 Million USD | 0.0% |
| 2021 Q1 | -1.28 Million USD | -10827.66% |
| 2021 Q3 | -216.71 Thousand USD | -59452.47% |
| 2021 Q2 | -363.91 USD | 99.97% |
| 2020 Q3 | -5032.00 USD | 58.19% |
| 2020 Q4 | -11.79 Thousand USD | -134.48% |
| 2020 Q1 | -30.44 Thousand USD | 15.05% |
| 2020 Q2 | -12.03 Thousand USD | 60.47% |
| 2019 Q1 | -38.89 Thousand USD | 5.17% |
| 2019 FY | -121.31 Thousand USD | 9.72% |
| 2019 Q4 | -35.84 Thousand USD | 16.64% |
| 2019 Q3 | -42.99 Thousand USD | -49.38% |
| 2019 Q2 | -28.78 Thousand USD | 26.0% |
| 2018 Q3 | -25.68 Thousand USD | 49.25% |
| 2018 Q4 | -41.01 Thousand USD | -59.72% |
| 2018 Q1 | -64.54 Thousand USD | 49.2% |
| 2018 Q2 | -50.6 Thousand USD | 21.6% |
| 2018 FY | -134.37 Thousand USD | 59.77% |
| 2017 Q2 | -116.2 Thousand USD | 34.06% |
| 2017 Q1 | -176.22 Thousand USD | -51328.2% |
| 2017 Q3 | -91.78 Thousand USD | 21.02% |
| 2017 Q4 | -127.06 Thousand USD | -38.44% |
| 2017 FY | -333.99 Thousand USD | -14.21% |
| 2016 Q1 | -15.26 Thousand USD | 80.1% |
| 2016 FY | -292.43 Thousand USD | -66.98% |
| 2016 Q4 | 344.00 USD | 198.57% |
| 2016 Q2 | -25.05 Thousand USD | -64.17% |
| 2016 Q3 | -349.00 USD | 98.61% |
| 2015 Q1 | -69.24 Thousand USD | -157.58% |
| 2015 Q3 | -58.1 Thousand USD | 5.02% |
| 2015 FY | -175.12 Thousand USD | 16.16% |
| 2015 Q4 | -76.7 Thousand USD | -32.01% |
| 2015 Q2 | -61.17 Thousand USD | 11.67% |
| 2014 Q3 | -51.57 Thousand USD | 0.0% |
| 2014 FY | -208.87 Thousand USD | -317.76% |
| 2014 Q4 | -26.88 Thousand USD | 47.87% |
| 2013 FY | -50 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2.72% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 72.807% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 92.314% |
| Nascent Biotech, Inc. | -2.22 Million USD | 38.483% |
| Rebus Holdings, Inc. | -664 Thousand USD | -106.59% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.676% |
| Qrons Inc. | -643.67 Thousand USD | -113.112% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -252.121% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.529% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -230.163% |
| Skye Bioscience, Inc. | -13.67 Million USD | 89.967% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.089% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 127.911% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -424.119% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.191% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 51.877% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 10.696% |
| Mesoblast Limited | -84.14 Million USD | 98.37% |
| Marizyme, Inc. | -34.08 Million USD | 95.976% |
| Genus plc | 6.4 Million USD | 121.434% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 114.08% |
| Pharming Group N.V. | -4.87 Million USD | 71.888% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 30.945% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -47.282% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 83.572% |
| ContraFect Corporation | -56.88 Million USD | 97.589% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 69.883% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 2.157% |
| IMV Inc. | -38.67 Million USD | 96.453% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 50.133% |
| MultiCell Technologies, Inc. | -722.81 USD | -189680.994% |
| ONE Bio Corp. | 13.68 Million USD | 110.026% |
| Accustem Sciences Inc. | -3.74 Million USD | 63.385% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.675% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -183.971% |
| Q BioMed Inc. | -3.44 Million USD | 60.188% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 138.75% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 47.793% |
| Biomind Labs Inc. | -1 Million USD | -35.871% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.505% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 52.718% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 79.366% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 26.423% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -4479.848% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.356% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 29.021% |
| GB Sciences, Inc. | -1.42 Million USD | 3.432% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.866% |
| HST Global, Inc. | -140.9 Thousand USD | -873.519% |
| CSL Limited | 3.7 Billion USD | 100.037% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -21.944% |
| Halberd Corporation | -75.05 Thousand USD | -1727.789% |
| Enzolytics Inc. | -2.14 Million USD | 36.162% |
| Resverlogix Corp. | -12.74 Million USD | 89.24% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 56.703% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.677% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -31.394% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 53.013% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 13.145% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 59.713% |
| AVAX Technologies, Inc. | 6.69 Million USD | 120.496% |
| Zenith Capital Corp. | -8.94 Million USD | 84.661% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.67% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7774.152% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 44.131% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -699.813% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 31.575% |
| Kadimastem Ltd | -3.04 Million USD | 54.88% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -39.399% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -9.216% |
| BioStem Technologies, Inc. | -7.77 Million USD | 82.366% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -655.851% |
| LadRx Corporation | -3.82 Million USD | 64.124% |
| Cell Source, Inc. | -4.32 Million USD | 68.286% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -99.688% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -99.688% |
| NovAccess Global Inc. | -2.46 Million USD | 44.39% |
| Affymax, Inc. | -15.04 Million USD | 90.883% |
| Itoco Inc. | -919.14 Thousand USD | -49.243% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 67.635% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -22.588% |
| Mobile Lads Corp. | -554.55 Thousand USD | -147.364% |
| CytoDyn Inc. | -18.05 Million USD | 92.404% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -5349.964% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -523.304% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -142.908% |
| SYBLEU INC | -149.18 Thousand USD | -819.531% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 24.476% |
| International Stem Cell Corporation | -663 Thousand USD | -106.901% |
| Bioxytran, Inc. | -3.82 Million USD | 64.092% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2505.919% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -6644.13% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.218% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 15.219% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -86.422% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 55.906% |
| Neutra Corp. | -229.48 Thousand USD | -497.751% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 92.179% |
| PureTech Health plc | -146.19 Million USD | 99.062% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 93.617% |
| IXICO plc | -1.43 Million USD | 4.54% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 85.547% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.874% |
| CSL Limited | 3.81 Billion USD | 100.036% |
| Cellectis S.A. | -108.85 Million USD | 98.74% |